Efficacy and Safety of Liraglutide and Semaglutide on Weight Loss in People with Obesity or Overweight: A Systematic Review
Zeyu Xie,Sensen Yang,Weishang Deng,Jinjian Li,Jisheng Chen
DOI: https://doi.org/10.2147/CLEP.S391819
2022-12-06
Clinical Epidemiology
Abstract:Zeyu Xie, Sensen Yang, Weishang Deng, Jinjian Li, Jisheng Chen Key Specialty of Clinical Pharmacy, the First Affiliated Hospital of Guangdong Pharmaceutical University, Guangzhou, People's Republic of China Correspondence: Jisheng Chen, Key Specialty of Clinical Pharmacy, the First Affiliated Hospital of Guangdong Pharmaceutical University, Guangzhou, 510080, People's Republic of China, Tel +86+20-87622305, Fax +86+20-61321967, Email Purpose: The effect and safety of Semaglutide and Liraglutide on weight loss in people with obesity or overweight were evaluated by a Network Meta-Analysis system to provide an evidence-based reference for clinical treatment. Methods: Computer searched PubMed, Embase, and Cochrane Library databases to collect Liraglutide and Semaglutide injection monotherapy RCTs until April 2022, using Stata 16 software for Network Meta-Analysis. Results: Twenty-three RCTs study with 11,545 patients and 4 interventions (semaglutide 2.4mg, semaglutide 1.0mg, liraglutide 3.0mg and liraglutide 1.8 mg) were finally included. In terms of efficacy, semaglutide 2.4mg (− 12.47 kg) had the best weight loss, followed by liraglutide 3.0mg (− 5.24 kg), semaglutide 1.0mg (− 3.74 kg) and liraglutide 1.8mg (− 3.29 kg). In terms of decreased HbA1c, semaglutide 2.4mg (MD=− 1.48%, 95% CI [− 1.93, − 1.04]), semaglutide 1.0mg (MD=− 1.36%, 95% CI [− 1.72, − 1.01]), liraglutide 1.8mg (MD=− 1.23%, 95%Cl [− 1.66, − 0.80]) more effective than placebo. In terms of safety, the total incidence of adverse events was semaglutide 2.4mg > liraglutide 3.0mg > liraglutide 1.8mg > semaglutide 1.0mg compare to placebo, the incidence of serious adverse events was liraglutide 3.0mg > liraglutide 1.8mg > semaglutide 2.4mg > semaglutide 1.0mg, the incidence of hypoglycemic events was semaglutide 2.4mg > liraglutide 3.0mg > semaglutide 1.0mg > liraglutide 1.8mg. Conclusion: This meta-analysis indicates that all GLP-1RAs were more efficacious than placebo in people with obesity or overweight on efficacy. Semaglutide 2.4mg has an absolute advantage in weight loss and decreased HbA1c, but the incidence of total adverse events is also the highest and can cause hypoglycemia. In addition, although liraglutide 3.0mg was less effective than semaglutide 2.4mg, serious adverse events were still the most elevated. Keywords: glucagon-like peptide-1 receptor agonists, weight loss, systematic review, liraglutide, semaglutide Obesity is a chronic disease with serious health consequences; it can lead to insulin resistance, hypertension, and dyslipidemia, associated with complications such as type 2 diabetes, cardiovascular disease, and non-alcoholic fatty liver disease, and reduce life expectancy. 1–4 Recently, obesity has been associated with increased hospitalizations, the need for mechanical ventilation, and death in patients with coronavirus disease 2019 (Covid-19). 5,6 Weight loss of 5% to 10% has been shown to reduce obesity-related complications and improve quality of life. 7,8 However, it is difficult to maintain weight loss with lifestyle interventions alone. 9 Clinical guidelines recommend adjunctive medical therapy, especially for adults with a BMI of 30 or higher or those with comorbidities of 27 or higher. 10 glucagon-like peptide-1 receptor agonists (GLP-1RA) activate GLP-1 receptors by mimicking natural GLP-1, enhance insulin secretion, inhibit glucagon secretion in a glucose concentration-dependent manner, and can delay gastric emptying, reducing food intake through central appetite suppression not only has the effect of lowering blood sugar, but also has the effect of weight loss. 11 The purpose of this study was based on the 2 GLP-1RA drugs (Liraglutide and Semaglutide) recommended in the diabetes prevention and control guidelines issued by the American Diabetes Association in 2022 12 and approved by the Food and Drug Administration (FDA), using Network Meta-Analysis (NMA) to objectively evaluate the weight loss effect and safety of subcutaneous injection of liraglutide and semaglutide in people with obesity or overweight, and provide evidence-based medical evidence for clinical practice. The Preferred Reporting Items report this systematic review and NMA for Systematic Reviews and Meta‐Analyses (PRISMA) statement. The study protocol was registered (registration number: CRD42022345166) with the International Prospective Register of Systematic Reviews (PROSPERO). Computer search PubMed, Cochrane Library, Embase database, the search time limit is from the establishment of the database to April 2022, and use the combination of subject headings and free words. Search subject terms include: Weight Loss, Glucagon-Like Peptide 1, Liraglutide, Semaglutide, R -Abstract Truncated-
public, environmental & occupational health